Rani Therapeutics Holdings, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Rani Therapeutics Holdings, Inc. on May 28, 2026. The record date for the meeting was April 2, 2026. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date, there were 99,812,515 shares of Class A common stock and 23,970,359 shares of Class B common stock outstanding. Both classes voted together as a single class. All proposals were approved:
- Director Elections: Stockholders elected seven director nominees to serve until the 2027 annual meeting. Significant broker non-votes (19,921,604) were recorded for all nominees.
- Accounting Firm Ratification: Stockholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares outstanding and the specific breakdown of Class A vs. Class B voting power.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 16, 2026) for detailed biographies of the elected directors and the rationale for the auditor selection.
- Confirm the impact of the high volume of broker non-votes on the effective voting threshold for future proposals.